Reforgene Medicine is a leading pioneer in the field of gene-editing therapeutics, headquartered in China. Our core competency lies in leveraging state-of-the-art CRISPR and genomic technologies to catalyze the development of novel, transformative medicines. Our technological acumen spans an extensive range of capabilities, from the innovation of proprietary gene-editing platforms to drug discovery pipelines, from the establishment of unique in vivo and in vitro preclinical models to comprehensive pharmacokinetic and safety profiling. Guided by our mission to harness innovative gene-editing modalities for the development of accessible and curative therapies, we have constructed a robust pipeline that addresses unmet medical needs across various therapeutic areas including genetic disorders, complex diseases, and oncology.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Number 801, Building 4, Rd 188, Kaiyuan Avenue, Huangpu, Guangzhou,guangdong 510000,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.reforgene.com
- Keywords
- 北京市.
- HQ
- Guangzhou, Guangdong
Reforgene Medicine Questions
Reforgene Medicine's website is http://www.reforgene.com
Reforgene Medicine's LinkedIn profile is https://cn.linkedin.com/company/reforgene
Reforgene Medicine has
4 employees.
View email and phone details for 4
employees at Reforgene Medicine.
Reforgene Medicine's industry is
Biotechnology Research
Reforgene Medicine's top competitors are
Genecast Group Inc.,
Alchemedicine, Inc.,
Epigenic Therapeutics,
Geneplus Co. Ltd,
臻和(北京)科技有限公司,
Relentless Health,
Kinetic,
Genecast,
Diagnose Early Detection,
Guangzhou Bio-Gene Technology Co., Ltd.
Reforgene Medicine's categories are Biotechnology Research
Reforgene Medicine's founding year is 2019
